MOBIC
LOE ApproachingNDAORALTABLET
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
3/8 — Basic
MOBIC by Boehringer Ingelheim is 12. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOBIC (meloxicam) is an oral NSAID tablet approved in 2000 that works by inhibiting cyclooxygenase (prostaglandin synthetase) to reduce prostaglandins, thromboxanes, and prostacyclin formation. The exact mechanism by which reduced prostaglandin synthesis achieves therapeutic benefit is not completely understood. It is primarily used for pain and inflammatory conditions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive commercial strategy and potential team right-sizing.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclo-oxygenase) inhibition which is involved in the initial steps of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
MobiChina - A Prospective Multicenter Cohort Study
Started Apr 2015
284 enrolled
Unstable FractureHip Fracture
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Started Nov 2008
6 enrolled
Healthy
Safety and Efficacy of Mobic Inj. (Meloxicam) for the Patients With OA or RA: Observational Study
Started Mar 2004
425 enrolled
OsteoarthritisArthritis, Rheumatoid
Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions
Started Jul 2003
121 enrolled
Arthritis, Rheumatoid
Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases
Started May 2003
12,687 enrolled
Osteoarthritis
Worked on MOBIC at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.